GDC-6036

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

GDC-6036 is an experimental drug currently being studied in clinical trials for certain types of advanced or metastatic solid tumors, including colorectal cancer. It is specifically being investigated in patients whose tumors have a KRAS G12C mutation. This mutation is a change in the KRAS gene, which can cause cancer cells to grow and spread. GDC-6036 is being tested to see if it is safe, how the body processes it (pharmacokinetics), and if it shows early signs of effectiveness (preliminary activity) in these patients. It is being studied alone and in combination with other cancer drugs like atezolizumab, bevacizumab, cetuximab, erlotinib, GDC-1971, and inavolisib. This is a Phase 1 trial, which means the primary goal is to determine the safest dose and understand how the drug works in people.

Mechanism of Action

GDC-6036 is designed to target the KRAS G12C protein, which is found in some cancer cells. The specific way GDC-6036 interacts with this protein is being studied. By targeting this protein, the drug aims to potentially stop or slow down the growth and spread of cancer cells that have this specific mutation.

Side Effects

As GDC-6036 is an experimental drug in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of Phase 1 trials is safety So researchers are carefully monitoring participants for any adverse events. Information about specific side effects observed in the NCT04449874 trial is not available in the provided data. Common side effects for drugs in this class or used in combination are often related to the immune system Gastrointestinal issues Fatigue Or skin reactions But this is not specific to GDC-6036.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04449874 Phase 1
Active, not recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
United States, Australia, Belgium, Brazil, Canada, Hungary, Israel, Italy, Kenya

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.